Novavax, Inc. 8-K Filing Report: Key Insights & Financial Updates
Based on the provided XML section of the financial report, here are the key insights and information extracted:
- Entity Information:
- Name: Novavax, Inc.
- CIK (Central Index Key): 0001000694
- State of Incorporation: Delaware (DE)
- SEC File Number: 0-26770
- EIN (Employer Identification Number): 22-2816046
- Address: 700 Quince Orchard Road, Gaithersburg, MD 20878
- Phone Number: 240-268-2000
- Filing Information:
- Filing Type: 8-K
- Filing Date: January 13, 2025
- Stock Information:
- Common Stock: The company has common stock with a par value of $0.01 per share.
- Ticker Symbol: NVAX
- Exchange: NASDAQ
- Context and Unit Information:
- Reporting Period: The report pertains to a specific date, January 13, 2025.
- Currency: All amounts are reported in U.S. Dollars (USD).
- Shares: The unit of measurement for the report includes shares.
- XML Structure: The report utilizes XBRL (eXtensible Business Reporting Language) format, which is common for regulatory filings to ensure structured and machine-readable data.
Insights:
- Recent Filing: The filing is an 8-K, which typically reports unscheduled material events or corporate changes that are of importance to shareholders.
- Operational Location: The company is based in Gaithersburg, MD, which is significant for understanding its operational environment and potential market influences.
- Stock Market Presence: Being listed on NASDAQ indicates the company is publicly traded and subject to SEC regulations, which adds transparency and regulatory scrutiny.
- Par Value: The par value of the stock is quite low ($0.01), which is common for many companies, especially in the biotech sector, reflecting potential for growth.
This information is vital for investors and analysts assessing Novavax's financial condition, market position, and regulatory compliance.